Table 1.

Echocardiography parameters: echocardiography was performed at baseline then 6 weeks following treatment with vehicle or empagliflozin

	Ob-vehicle			Ob-empagliflozin
	Baseline	6 weeks follow-up	p	Baseline	6 weeks follow-up	p
Weight (g)	47.7 ±2.1	59.1 ±2.8	0.004	45.2 ± 2.9	53.3 ±4.8	0.002
Heart rate (beats/min)	580 ± 42	608 ± 35	0.82	565 ± 39	568 ±52	1
LV diastolic diameter (mm)	3.1 ±0.2	2.9 ± 0.2	0.31	2.9 ± 0.2	3.0 ± 0.2	0.50
LV systolic diameter (mm)	1.5 ±0.2	1.4 ±0.1	0.44	1.5 ±0.3	1.6 ±0.3	0.43
LV mass (mg)	89.7 ± 12.2	83.6 ± 13.3	0.44	79.2 ± 8.9	82.4 ± 8.2	0.70
LVFS (%)	51.0 ±6.3	52.6 ±4.8	0.81	48.2 ± 7.5	46.1 ± 5.8	0.23
LVEF (%)	87.0 ± 4.5	88.6 ±3.2	0.63	84.7 ± 5.5	82.9 ± 5.6	0.20
E (cm/s)	76 ± 6.3	72.2 ±6.5	0.13	80.4 ± 11.6	66.1 ± 13.7	0.03
DT (ms)	28.8 ± 2.8	28.2 ±5.6	0.81	29.8 ± 3.2	26.2 ± 2.7	0.02

Data expressed as mean ± standard deviation (n = 10–15/group)

LV left ventricular, LVEF left ventricular ejection fraction, LVFS left ventricular fractional shortening, E mitral inflow peak velocity, DT E wave deceleration time